

2024



May 2023: NIDA Director Nora Volkow, M.D., issues a statement on how the connection between HIV and substance use disorders can be further complicated by other factors in life, highlighting the importance of comprehensive stigma-free harm reduction. See [“Still Reaching: The Syndemics that Complicate and Characterize How Drugs and HIV Intersect in People’s Lives.”](#)



July 2024: NIDA Director Nora Volkow, M.D., and Dr. Jeanne Marrazzo, Director of the National Institute of Allergy and Infectious Diseases, encourage stronger overdose education and naloxone distribution for patients in HIV care settings. See [“We should leverage the successes of HIV care to prevent overdose mortality.”](#)

2023



August 2023: NIDA research contributes to a new U.S. Preventive Services Task Force [Grade A final recommendation statement](#) on pre-exposure prophylaxis (PrEP) for the prevention of HIV among those at increased risk, including people who inject drugs.




May 2023: NIDA Director Nora Volkow, M.D., issues a [statement](#) on the syndemics at the intersection of HIV and drug use and the importance of harm reduction policies.

2022



November 2022: NIDA issues new videos, "[Sex, Meth and HIV](#)" and "[Trust, Stigma and Patient Care](#)," to reduce stigma related to methamphetamine use and HIV.

2022



October 2022: NIDA launches an ongoing [Seminar Series](#) offering improved access to cutting edge research at the intersection of HIV and substance use.

October 2022: The renewed NIDA HIV Working Group is launched; providing an opportunity for scientists across NIH to discuss initiatives and collaborations related to HIV and AIDS science.



August 2022: NIDA [issues](#) four new Funding Opportunity Announcements (FOAs) that are part of NIDA's Racial Equity Initiative, with goals that include promoting racial equity in NIDA's research portfolio.


2021





December 2021: On World AIDS Day, NIDA Director Dr. Nora D. Volkow issues a [statement](#) highlighting NIDA -funded innovations in HIV research, including the comprehensive [syringe services program](#) led by Avenir Award awardee Dr. Hansel E. Tookes, III.

▲ Image Courtesy NIDA/ Sonya Revell, Photographer

2021



October 2021: NIDA renames its AIDS Research Program the [NIDA HIV Research Program \(HRP\)](#) to reduce stigmatizing language, and to better reflect the evolving scientific focus on the virus itself and the intertwining epidemic of substance use disorders.




June 2021: NIDA issues a [Notice of Special Interest](#) in epidemiological investigations to quantify the impact of the coronavirus disease 2019 (COVID-19) pandemic on human immunodeficiency virus (HIV) prevention, incidence, transmission, and outcomes.



February 2021: [The Centers for Disease Control and Prevention lists HIV as a high-risk medical condition](#), and those patients should receive SARS-CoV-2 vaccines, regardless of CD4 or viral load, because the potential benefits outweigh potential risks.

2020




December 2020: On World AIDS Day 2020, NIDA Director Dr. Nora D. Volkow posts a [blog](#) highlighting the substantial strides in HIV research supported by NIDA over the past 3 decades.

2020



November 2020: In collaboration with NIMHD, NIDA issues two funding opportunities to [stimulate multi-level prevention](#) and [cost-effective care innovations](#) with a focus on highest risk and health disparities populations.



July 2020: NIDA Director Dr. Nora D. Volkow posts a [blog entry](#) on research at the intersection of HIV, COVID-19, and the opioid crisis.

February 2020: NIDA releases funding opportunity "[Implementing the HIV Service Cascade for Justice-Involved Populations](#)" to address research gaps related to integrated HIV and opioid use disorder services among justice-involved patients.

▲ Scanning electromicrograph of an HIV-infected T cell. Credit: NIAID

2019



September 2019: ARP Director Dr. Redonna K. Chandler presents updated NIDA HIV "High Priority" Research Areas to NIDA Council. (See 2:00:00 in [this videocast](#).)

July 2019: NIDA contributes to a [funding opportunity to stimulate research on interventions to reduce HIV-associated stigma](#) and its impact on prevention and treatment of HIV and on quality of life.



July 2019: NIDA Director Dr. Nora D. Volkow presents "[Opioid Use Disorders: Impact on HIV](#)" at the 2019 International AIDS Conference.

▲ Credit: International AIDS Society/Steve Forrest/Workers' Photos

2018



- | **November 2018:** NIDA holds two [strategic planning workshops](#) to identify research gaps and opportunities for advancement of science at the intersection of HIV and substance use disorders.
- | **June 2018:** NIDA appoints [Dr. Vasundhara Varthakavi](#) as its first Associate Director for the NIDA AIDS Research Program.
- | **January 2018:** NIDA appoints [Dr. Redonna K. Chandler](#) as Director of the NIDA AIDS Research Program.

2015



- | **September 2015:** NIDA-funded scientists publish a [JAIDS special supplement](#) documenting how the burdens of HIV, drug use, and their co-occurring epidemics affect women in a global context.
- | **June 2015:** NIDA issues its first [Avenir Awards](#) to early-stage investigators proposing innovative research at the intersection of substance use and HIV.

2013



- | **April 2013:** NIDA Director Dr. Nora D. Volkow and ARP Director Dr. Jacques Normand [visit Vietnam](#) to foster research collaborations between NIDA and Vietnamese scientists on issues of HIV and drug use.
- | **November 2013:** NIDA-funded scientists publish a [special supplement outlining needs of people who inject drugs in central Asia](#), calling for quality surveillance and monitoring systems, as well as in-country implementation research.

▲ Credit: PEPFAR Vietnam

2012

November 2012: [Blog post](#) by NIDA Director Dr. Nora D. Volkow highlights HIV treatment disparities for people who inject drugs as an obstacle to achieving an AIDS-free generation.

2011



February 2011: NIDA issues a [funding opportunity announcement soliciting implementation science research to support PEPFAR](#) development of more efficient and cost-effective methods to deliver HIV prevention, treatment, and care for populations who use drugs.

2010



November 2010: NIDA releases [video interviews](#) with top scientists studying HIV in populations who use drugs from the 2010 International AIDS Conference.



June 2010: NIDA announces a funding opportunity encouraging the development and evaluation of [strategies to address HIV among vulnerable populations using seek, test, treat, and retain paradigms](#).

2009

November 2009: NIDA releases a funding opportunity for [interventions based on the seek, test, treat, and retain model to address HIV in the criminal justice system.](#)

2008



September 2008: NIDA issues its first [Avant-Garde Awards](#) to support creative scientists who propose high-impact research that will open new areas of HIV research related to drug use.

2007



April 2007: NIDA [launches A-START initiative](#) to expand drug use and HIV research funding opportunities for new and early career investigators.

February 2007: NIDA issues [new policy on HIV Education, Counseling, Testing, and Treatment for Research Subjects.](#)

2004



Spring 2004: NIDA establishes the AIDS Research Program (ARP) with Dr. Jacques Normand as its director.